NCT06888830

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 374 (estimated)
• Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour. Patients will be enrolled in two stages: a dose-escalation stage and a dose expansion stage.

Conditions

• Advanced Malignant Solid Tumours

Interventions

Type	Name	Description
DRUG	JS212 for Injection	JS212 for Injection is administered on the first day of the first cycle and every 3 weeks thereafter.

Timeline

• Start date: 2025-04-11
• Primary completion: 2026-07-01
• Completion: 2027-04-01
• First posted: 2025-03-21
• Last updated: 2025-06-19

Locations

1 site across 1 country: China